The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Can we identify patients at risk for discordance in preferred and actual role in cancer treatment decision making?
Leah L. Zullig
No relevant relationships to disclose
Christel Rushing
No relevant relationships to disclose
Fumiko Ladd Chino
No relevant relationships to disclose
Greg Samsa
No relevant relationships to disclose
Ivy Altomare
No relevant relationships to disclose
James A Tulsky
No relevant relationships to disclose
Peter A Ubel
No relevant relationships to disclose
Jonathan Nicolla
No relevant relationships to disclose
Amy Pickar Abernethy
Employment or Leadership Position - Advoset (U); American Academy of Hospice and Palliative Medicine; Orange Leaf Associates (U)
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Celgene; DARA BioSciences; Dendreon; Helsinn Therapeutics; Pfizer
Jeffrey M. Peppercorn
Employment or Leadership Position - GlaxoSmithKline (I)
Stock Ownership - GlaxoSmithKline (B)
Yousuf Zafar
Consultant or Advisory Role - Genentech (U)